SCHEMBL328911

SCHEMBL328911

COC(=O)C12CC3CC(C1)C(N1CC(CO)C(C)(C)C1=O)C(C3)C2

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 12/20 0.49
HSD11B2 P80365 7/20 0.49
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
SCN9A Q15858 2/20 0.34
EPHX2 P34913 2/20 0.32
SCN1A P35498 1/20 0.32
SCN2A Q99250 1/20 0.32
SCN3A Q9NY46 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL328788 0.79 HSD11B1 (0.51) HSD11B1HSD11B2HPGD
SCHEMBL328784 0.77 HSD11B1 (0.83) HSD11B1HSD11B2
SCHEMBL362309 0.77 HSD11B1 (0.46) HSD11B1HSD11B2
SCHEMBL328814 0.75 HSD11B1 (0.84) HSD11B1HSD11B2
SCHEMBL328901 0.75 HSD11B1 (0.84) HSD11B1HSD11B2ALDH1A1LMNAHPGD
SCHEMBL328952 0.74 HSD11B1 (0.48) HSD11B1HSD11B2ALDH1A1HPGD
SCHEMBL2168951 0.72 HSD11B1 (0.39) HSD11B1HSD11B2ALDH1A1LMNASCN9A
SCHEMBL2169249 0.72 HSD11B1 (0.39) HSD11B1HSD11B2ALDH1A1LMNASCN9A
SCHEMBL2168949 0.72 HSD11B1 (0.39) HSD11B1HSD11B2ALDH1A1LMNASCN9A
SCHEMBL2169254 0.72 HSD11B1 (0.39) HSD11B1HSD11B2ALDH1A1LMNASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007719-B1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LAB (US) 2012-05-02 EP disclosed
EP-2407452-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme Abbott Laboratories (US) 2012-01-18 EP disclosed
US-7737137-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2010-06-15 US disclosed
US-20080312214-A1 Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme ABBOTT LABORATORIES (US) 2008-12-18 US disclosed
US-7435833-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2008-10-14 US disclosed
US-20080076819-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076819-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885HSD11B2 2/4885ALDH1A1 132/4885
US-20080312214-A1 Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885ALDH1A1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.